Literature DB >> 14961578

Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients.

Asma Gati1, Sylvie Da Rocha, Nadia Guerra, Bernard Escudier, Alessandro Moretta, Salem Chouaib, Eric Angevin, Anne Caignard.   

Abstract

Metastatic renal cell carcinomas (MRCC) are considered as immunogeneic tumors on the basis of the clinical responses observed in patients treated by IL-2. However, renal cell carcinoma patients are also characterized by alterations of the immune response that may compromise the immunotherapeutic approaches. In our study, we have studied the phenotype and the functional capacities of peripheral NK cells in a panel of neprectomized metastatic renal cell carcinoma patients. NK cells were harvested by negative immunoselection from fresh peripheral blood samples. In most of MRCC patients analysed (23/28), the expression of NCR (NKp46 and NKp30) was similar to that of donors. Lytic capacities by activated immunoselected NK cells from MRCC patients assessed against K562 and 3 renal tumor cell lines were in the range of that observed in NK cells from normal donors. HLA-I- renal tumor cells UOK23 were killed with a good efficiency, whereas HLA-I renal tumor cells were more resistant. Although LFA-1/ICAM-1 interaction potentiates RCC cell lysis, HLA-I/NKR interaction clearly decreased RCC cell susceptibility to NK cells. In addition, proliferation of NK cells from MRCC patients in response to cytokines was altered. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14961578     DOI: 10.1002/ijc.11730

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha.

Authors:  E Juengel; M Bhasin; T Libermann; S Barth; M Michaelis; J Cinatl; J Jones; L Hudak; D Jonas; R A Blaheta
Journal:  World J Urol       Date:  2010-07-17       Impact factor: 4.226

2.  Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Authors:  Katherine A Murphy; Britnie R James; Yue Guan; Donald S Torry; Andrew Wilber; Thomas S Griffith
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Authors:  Matthew K Labriola; Kristen A Batich; Jason Zhu; Megan A McNamara; Michael R Harrison; Andrew J Armstrong; Daniel J George; Tian Zhang
Journal:  Clin Genitourin Cancer       Date:  2019-02-05       Impact factor: 2.872

Review 4.  The Yin and Yang of HLA and KIR in human disease.

Authors:  Smita Kulkarni; Maureen P Martin; Mary Carrington
Journal:  Semin Immunol       Date:  2008-07-16       Impact factor: 11.130

Review 5.  The immunoregulatory mechanisms of carcinoma for its survival and development.

Authors:  Caigan Du; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-01-21

6.  NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies.

Authors:  Giulia Fregni; Aurélie Perier; Marie-Françoise Avril; Anne Caignard
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

7.  Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients.

Authors:  Xiaojie Tan; Songqin He; Yifang Han; Yongwei Yu; Jianru Xiao; Danfeng Xu; Guoping Wang; Yan Du; Wenjun Chang; Jianhua Yin; Tong Su; Jianguo Hou; Guangwen Cao
Journal:  Cancer Cell Int       Date:  2013-02-26       Impact factor: 5.722

Review 8.  Tumor-primed NK cells: waiting for the green light.

Authors:  May Sabry; Mark W Lowdell
Journal:  Front Immunol       Date:  2013-11-25       Impact factor: 7.561

Review 9.  Obesity and renal cancer: Role of adipokines in the tumor-immune system conflict.

Authors:  Asma Gati; Soumaya Kouidhi; Raja Marrakchi; Amel El Gaaied; Nadia Kourda; Amine Derouiche; Mohamed Chebil; Anne Caignard; Aurélie Perier
Journal:  Oncoimmunology       Date:  2014-01-16       Impact factor: 8.110

Review 10.  Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.

Authors:  Carin I M Dahlberg; Dhifaf Sarhan; Michael Chrobok; Adil D Duru; Evren Alici
Journal:  Front Immunol       Date:  2015-11-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.